Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANZAR: Dato-DXd + Durvalumab + Carboplatin vs Pembrolizumab + Chemotherapy in 1L Advanced/Metastatic NSCLC
NCT05687266Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-Free Survival at 3 years and Overall Survival at 5 years. Started Dec 2022; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05687266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687266.